- Home
- FKWL vs BCAB Comparison
FKWL vs BCAB Comparison
Compare FKWL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FKWL
- BCAB
- Stock Information
- Founded
- FKWL 1981
- BCAB 2007
- Country
- FKWL United States
- BCAB United States
- Employees
- FKWL N/A
- BCAB N/A
- Industry
- FKWL Telecommunications Equipment
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- FKWL Utilities
- BCAB Health Care
- Exchange
- FKWL Nasdaq
- BCAB Nasdaq
- Market Cap
- FKWL 45.8M
- BCAB 40.5M
- IPO Year
- FKWL 1996
- BCAB 2020
- Fundamental
- Price
- FKWL $5.09
- BCAB $0.64
- Analyst Decision
- FKWL Strong Buy
- BCAB Hold
- Analyst Count
- FKWL 1
- BCAB 3
- Target Price
- FKWL $6.00
- BCAB $1.00
- AVG Volume (30 Days)
- FKWL 17.1K
- BCAB 1.2M
- Earning Date
- FKWL 11-14-2025
- BCAB 11-13-2025
- Dividend Yield
- FKWL N/A
- BCAB N/A
- EPS Growth
- FKWL N/A
- BCAB N/A
- EPS
- FKWL N/A
- BCAB N/A
- Revenue
- FKWL $46,086,901.00
- BCAB $11,000,000.00
- Revenue This Year
- FKWL N/A
- BCAB N/A
- Revenue Next Year
- FKWL $35.96
- BCAB N/A
- P/E Ratio
- FKWL N/A
- BCAB N/A
- Revenue Growth
- FKWL 49.65
- BCAB N/A
- 52 Week Low
- FKWL $3.67
- BCAB $0.24
- 52 Week High
- FKWL $7.45
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- FKWL 64.17
- BCAB 45.11
- Support Level
- FKWL $4.98
- BCAB $0.60
- Resistance Level
- FKWL $5.18
- BCAB $0.69
- Average True Range (ATR)
- FKWL 0.15
- BCAB 0.07
- MACD
- FKWL -0.03
- BCAB -0.01
- Stochastic Oscillator
- FKWL 36.67
- BCAB 19.35
About FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.